Galician public health service providing clinical infrastructure, patient cohorts, and biomedical research across infectious disease, neurodegeneration, and digital health in EU consortia.
SERGAS is the public health service of Galicia, Spain, operating hospitals and research units across the region. In H2020, they contributed clinical infrastructure, patient cohorts, and biomedical research expertise — particularly in infectious disease diagnostics, neurodegenerative disease biomarkers, and pediatric clinical trials. Their hospitals serve as real-world clinical validation sites for diagnostic tools, digital health platforms, and personalized medicine approaches developed within European consortia. They bridge the gap between laboratory research and bedside application within a large regional healthcare system.
PERFORM, DIAMONDS, PoC-ID, and ZIKAction all focus on molecular diagnostics, biomarkers for bacterial vs viral infection, and point-of-care testing for infectious diseases.
RESCEU and PROMISE form a continuous RSV research thread covering surveillance, burden of disease estimation, and immunisation preparedness across Europe.
PANA targeted Alzheimer's nanodiagnostics (their only coordinated project), MADIA developed magnetic diagnostic assays for neurodegeneration, and RESSTORE investigated stem cell therapy for stroke recovery.
c4c (their largest funded project at EUR 2.26M) builds European clinical trial networks for children, while ZIKAction focused on maternal-paediatric infection pathology.
PERSIST applies AI and big data to cancer survivorship care, TIMELY builds early risk prediction for cardiovascular patients, and ACTIVAGE deployed IoT for ageing well.
Olive-Net investigated oleocanthal, oleacein, and other bioactive compounds from Olea europaea for nutraceutical, cosmetic, and pharmaceutical applications.
In their early H2020 period (2015–2018), SERGAS focused heavily on regenerative medicine, stem cell therapy for stroke, point-of-care infectious disease diagnostics, and cardiac rehabilitation — classic clinical research in established biomedical domains. From 2019 onward, their portfolio shifted toward digital health tools (AI-driven survivorship care, predictive cardiology platforms), personalized molecular diagnostics (RNA-based fever management in DIAMONDS), and radiation risk assessment. The thread of infectious disease expertise remained constant throughout, but the methods evolved from traditional biomarkers toward molecular and data-driven approaches.
SERGAS is moving from traditional clinical trial participation toward data-intensive personalized medicine, making them a strong partner for projects combining clinical cohorts with AI or molecular profiling tools.
SERGAS operates overwhelmingly as a participant (15 of 16 projects), coordinating only once — the PANA Alzheimer's nanodiagnostics project. With 285 unique consortium partners across 36 countries, they are well-connected hub participants who bring clinical sites and patient access to large consortia rather than leading them. Their value to consortia is clearly as a trusted clinical partner providing real-world hospital infrastructure, patient recruitment capacity, and regulatory-compliant data collection in Spain.
With 285 unique partners across 36 countries, SERGAS has one of the broadest collaboration networks for a regional health service, reflecting their participation in large multi-site clinical consortia. Their reach spans all of Europe and extends globally through projects like ZIKAction addressing Latin American and Caribbean health challenges.
As Galicia's public health service, SERGAS offers something most academic partners cannot: direct access to a regional hospital network with real patient populations for clinical validation and prospective data collection. Their rare combination of infectious disease expertise, neurodegenerative disease research, and emerging digital health capabilities makes them versatile across multiple health domains. For consortium builders, SERGAS provides a Spanish clinical site with proven H2020 experience and the administrative capacity to manage significant EU funding (over EUR 10.6M received).
